All In Biotech

Drug Trial Radar · NCT06351631

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

May 23, 2024

Primary completion

Dec 4, 2034

Study completion Dec 4, 2034

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria: * Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat; * Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic response. No hypothesis testing will be conducted in this study.

Conditions

  • Thrombocythemia, Essential
  • Primary Myelofibrosis
  • Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis
  • Polycythemia Vera

Interventions

  • BomedemstatDrug

    10, 15, 20, and 50 mg oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with one or more adverse events (AEs)Time frame: Up to ~10 years
  2. Percentage of participants who discontinued study treatment due to an AETime frame: Up to ~10 years

Locations

21 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Michigan ( Site 6000)

    Ann Arbor, Michigan · Recruiting

  • DUHS Duke Blood Cancer Center ( Site 6005)

    Durham, North Carolina · Recruiting

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007)

    Columbus, Ohio · Recruiting

  • UPMC Hillman Cancer Center ( Site 6004)

    Pittsburgh, Pennsylvania · Recruiting

  • Royal Prince Alfred Hospital ( Site 1003)

    Camperdown, New South Wales, Australia · Recruiting

  • Royal North Shore Hospital ( Site 1001)

    St Leonards, New South Wales, Australia · Recruiting

  • Sunshine Coast Hematology and Oncology Clinic ( Site 1006)

    Buderim, Queensland, Australia · Recruiting

  • Gold Coast University Hospital-Cancer and Blood Disorders Clinical Trial Team ( Site 1002)

    Southport, Queensland, Australia · Recruiting

  • Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 1000)

    Adelaide, South Australia, Australia · Recruiting

  • Monash Health ( Site 1004)

    Clayton, Victoria, Australia · Recruiting

  • Queen Mary Hospital ( Site 1601)

    Hksar, Hong Kong · Active not recruiting

  • Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2703)

    Alessandria, Italy · Recruiting

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 2702)

    Bologna, Italy · Recruiting

  • Ospedale di Circolo e Fondazione Macchi Varese ( Site 2701)

    Varese, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Careggi ( Site 2700)

    Florence, Tuscany, Italy · Recruiting

  • North Shore Hospital-Department of Haematology ( Site 1401)

    Auckland, New Zealand · Active not recruiting

  • Aotearoa Clinical Trials ( Site 1400)

    Auckland, New Zealand · Active not recruiting

  • Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 3402)

    London, Hammersmith and Fulham, United Kingdom · Recruiting

  • Boston Pilgrim Hospital ( Site 3403)

    Boston, Lincolnshire, United Kingdom · Recruiting

  • University College London Hospital ( Site 3400)

    London, London, City of, United Kingdom · Recruiting

  • Guy's & St Thomas' NHS Foundation Trust ( Site 3401)

    London, London, City of, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.